Boehringer Ingelheim: Pulmonary Disease, Chronic Obstructive trials

The registry lists 236 Pulmonary Disease, Chronic Obstructive studies with Boehringer Ingelheim as lead sponsor. 1 are open to participants now and 124 have results posted.

Phase 1 7Phase 2 33Phase 3 81Phase 4 32No phase 83(a study in two phases counts in both)

Studies

Page 2 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• 12 / 48 Week Pivotal PFT vs PBO in COPD ICompletedNCT00782210Phase 3Results posted
• Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00720499Phase 2Results posted
• Observational Non-Interventional Study With Spiriva Respimat in COPD PatientsCompletedNCT00699699Results posted
• Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)CompletedNCT00696020Phase 2Results posted
• Tiotropium/Salmeterol Inhalation Powder in COPDTerminatedNCT00668772Phase 3Results posted
• Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPDCompletedNCT00662792Phase 3Results posted
• Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)TerminatedNCT00662740Phase 3Results posted
• Special Survey Long-term Treatment With Tiotropium on COPDCompletedNCT00638183Results posted
• Safety and Effectiveness of Spiriva in COPD (Chronic Obstructive Pulmonary Disease) Patients Under the Real Condition of Usual PracticeCompletedNCT00624377Results posted
• Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease SeveritiesCompletedNCT00621582Results posted
• Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD GuidelinesCompletedNCT00615992Results posted
• RUSSE / Russian Spiriva® Safety & Efficacy StudyCompletedNCT00613574Results posted
• Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.CompletedNCT00563381Phase 4Results posted
• Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPDCompletedNCT00530842Phase 4Results posted
• An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.CompletedNCT00528996Phase 2Results posted
• Tiotropium In ExerciseCompletedNCT00525512Phase 4Results posted
• Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).CompletedNCT00523991Phase 4Results posted
• Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.CompletedNCT00452400Phase 2Results posted
• Effect of BIBW 2948 BS in COPDCompletedNCT00423137Phase 2Results posted
• Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00400153Phase 3Results posted
• Tiotropium / Respimat One Year Study in COPD.CompletedNCT00387088Phase 3Results posted
• A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.CompletedNCT00359788Phase 4Results posted
• Tiotropium / Respimat One-Year StudyCompletedNCT00168844Phase 3Results posted
• Tiotropium / Respimat One-Year StudyCompletedNCT00168831Phase 3Results posted
• Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD PatientsCompletedNCT00144339Phase 3Results posted
• Tiotropium Plus Olodaterol vs Inhaled Corticosteroids (ICS) Regimens in the Portuguese Primary Care Setting (TIOLCOR Study)WithdrawnNCT04402515
• TARA Working Prototype [Version 2]: Feasibility StudyWithdrawnNCT04320524Not applicable
• TARA Working Prototype Engagement Evaluation: Feasibility StudyCompletedNCT04085302Not applicable
• Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT02260011Phase 2
• Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02249338Phase 2
• Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT02249247Phase 2
• Postmarketing Surveillance Study of Berotec® N 100 µg Metered-dose Inhaler in Chronic Obstructive Respiratory Tract DiseaseCompletedNCT02244216
• Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD PatientsCompletedNCT02242279Phase 2
• Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02242266Phase 2
• Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02242253Phase 2
• Lung Function Changes Following the Addition of Formoterol to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02242240Phase 2
• Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02242227Phase 2
• Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary DiseaseCompletedNCT02238197
• Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02238184
• Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Pulmonary DiseaseCompletedNCT02238171
• Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary DiseaseCompletedNCT02238158
• Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways DiseaseCompletedNCT02238145
• Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Airways DiseaseCompletedNCT02238132
• Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02238119Phase 2
• Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02238106Phase 2
• Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways DiseaseCompletedNCT02236715
• Study to Assess the Safety of Ipratropium Bromide, in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02236182Phase 2
• Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02236169Phase 2
• Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive BronchitisCompletedNCT02233920
• Post-marketing Surveillance of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary DiseaseCompletedNCT02233907
• Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary DiseaseCompletedNCT02233894
• Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary DiseaseCompletedNCT02233881
• Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract DiseaseCompletedNCT02232594
• Post-marketing Surveillance of Berodual® Metered-dose Inhaler in the Treatment of Chronic Obstructive Respiratory Tract DiseaseCompletedNCT02231437
• Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways DiseaseCompletedNCT02231424
• Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways DiseaseCompletedNCT02231372
• Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways DiseaseCompletedNCT02231359
• Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Comparison to a Powder Inhaler in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT02231346
• Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT02231320
• A Prescription-Event Monitoring (PEM) Study of TiotropiumCompletedNCT02196194
• Comparison of Safety and Efficacy of COMBIVENT HFA to COMBIVENT (CFC) in Patients With Chronic Obstructive Pulmonary Disease (COPD)TerminatedNCT02194205Phase 3
• Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)TerminatedNCT02182869Phase 2
• Ipratropium or Salbutamol Sulphate Alone or Combination Therapy Salbutamol and Ipratropium in Patients With COPDCompletedNCT02182856Phase 4
• A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02182674Phase 2
• Ba253BINEB in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02182635Phase 3
• Ba253BINEB Compared to Ba253MDI (Metered Dose Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02182583Phase 3
• Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary DiseaseCompletedNCT02177344Phase 3
• Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT02177318
• Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary DiseaseCompletedNCT02177253Phase 3
• Inhaled Bronchodilator Association and Quality of Life in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT02176564
• Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)TerminatedNCT02176200Phase 3
• Berodual® Respimat® vs Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary DiseaseTerminatedNCT02176187Phase 3
• Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02175342Phase 2
• Berodual® Respimat® Versus Berodual® Metered Aerosol (MA) Inhaler in Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed ConditionCompletedNCT02173795Phase 3
• Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02173782Phase 3
• Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)CompletedNCT02173691Phase 3
• Efficacy and Safety of Ba679BR Powder Inhalation in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02172807Phase 3
• Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02172794Phase 3
• A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat InhalerCompletedNCT02172560
• Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.CompletedNCT02172547
• Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven HyperinflationCompletedNCT02172521
• Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary RehabilitationTerminatedNCT02172508Phase 4
• Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily PracticeCompletedNCT02172495
• Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02172482
• Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02172469Phase 3
• Evaluation of the Lung Deposition Rate and Distribution Pattern of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02172456Phase 3
• Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary DiseaseCompletedNCT02172443Phase 3
• Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02172430Phase 3
• HandiHaler® vs. Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02172404Phase 3
• Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02172391Phase 3
• 12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea ScalesCompletedNCT02172378Phase 3
• Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT02172352Phase 2
• Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)CompletedNCT02172326Phase 3
• Effect of Tiotropium on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02172300Phase 3
• Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02172287Phase 3
• Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive BronchitisWithdrawnNCT00726479Phase 2
• Tiotropium and Salmeterol PK Study in COPD PatientsCompletedNCT00673478Phase 3
• Tiotropium 18ug Inhalation Capsule Using a Handihaler® Among Korean COPD PatientsCompletedNCT00620516
• Observational Non-interventional Study With Spiriva in Chronic Obstructive Pulmonary Disease Patients With Exercise-induced DyspnoeaCompletedNCT00540163
• Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPDCompletedNCT00535366Phase 2